SLRX Salarius Pharmaceuticals, Inc. Stock Quote

SLRX [NASD]

Index	-	P/E	-	EPS (ttm)	-0.38	Insider Own	0.70%	Shs Outstand	46.26M	Perf Week	0.69%
Market Cap	11.11M	Forward P/E	-	EPS next Y	-0.47	Insider Trans	110.42%	Shs Float	43.88M	Perf Month	-44.34%
Income	-17.00M	PEG	-	EPS next Q	-0.10	Inst Own	10.10%	Short Float	1.37%	Perf Quarter	-55.96%
Sales	0.60M	P/S	18.52	EPS this Y	37.90%	Inst Trans	-21.94%	Short Ratio	0.55	Perf Half Y	-72.50%
Book/sh	0.72	P/B	0.26	EPS next Y	-2.70%	ROA	-40.50%	Target Price	4.25	Perf Year	-86.09%
Cash/sh	0.41	P/C	0.46	EPS next 5Y	-	ROE	-42.40%	52W Range	0.16 - 1.49	Perf YTD	-61.82%
Dividend	-	P/FCF	-	EPS past 5Y	65.20%	ROI	-33.10%	52W High	-86.94%	Beta	1.37
Dividend %	-	Quick Ratio	11.90	Sales past 5Y	12.70%	Gross Margin	-	52W Low	21.59%	ATR	0.04
Employees	16	Current Ratio	11.90	Sales Q/Q	-100.00%	Oper. Margin	-	RSI (14)	41.22	Volatility	19.15% 17.66%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	-117.90%	Profit Margin	-	Rel Volume	1.38	Prev Close	0.19
Shortable	Yes	LT Debt/Eq	0.00	Earnings	May 12 AMC	Payout	-	Avg Volume	1.09M	Price	0.19
Recom	1.00	SMA20	-5.86%	SMA50	-36.93%	SMA200	-68.28%	Volume	184,377	Change	2.83%

Apr-27-20

Initiated

Ladenburg Thalmann

Buy

$3.80

May-18-22 04:10PM	Salarius Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference GlobeNewswire +20.62%
May-12-22 04:05PM	Salarius Pharmaceuticals Reports Business Highlights with First Quarter 2022 Financial Results GlobeNewswire +38.75%
May-11-22 04:05PM	Salarius Pharmaceuticals Completes SP-3164 Pre-Investigational New Drug Meeting Process with the U.S. Food and Drug Administration GlobeNewswire -16.93%
May-05-22 07:30AM	Salarius Pharmaceuticals to Report First Quarter 2022 Financial Results and Highlight Recent Company Progress GlobeNewswire
Apr-22-22 08:30AM	Salarius Pharmaceuticals, Inc. Announces $2.3 Million Registered Direct Offering GlobeNewswire -20.54%
Mar-10-22 04:05PM	Salarius Pharmaceuticals Reports Business Highlights with Fourth Quarter and Full-Year 2021 Financial Results GlobeNewswire +33.40%
Mar-03-22 07:31AM	Salarius Pharmaceuticals to Report Fourth Quarter and Full-Year 2021 Financial Results and Highlight Recent Company Progress GlobeNewswire
Feb-17-22 08:01AM	Salarius Pharmaceuticals to Present at the Diamond Equity Research Emerging Growth Invitational 2022 Virtual Conference GlobeNewswire
Feb-15-22 09:00AM	Diamond Equity Research to Host Emerging Growth Invitational Virtual Investor Conference on February 24, 2022 GlobeNewswire
Feb-08-22 08:00AM	Salarius Pharmaceuticals to Participate in the 2022 BIO CEO & Investor Conference GlobeNewswire
Feb-03-22 07:30AM	Salarius Pharmaceuticals Appoints Daniela Santiesteban, Ph.D., to Director of Targeted Protein Degradation Program GlobeNewswire
Jan-14-22 01:52PM	Salarius expands oncology drug pipeline with DeuteRx portfolio acquisition American City Business Journals
Jan-13-22 07:00AM	Salarius Pharmaceuticals Expands Oncology Pipeline Through Strategic Acquisition of Targeted Protein Degradation Portfolio from DeuteRx, LLC GlobeNewswire
Jan-06-22 12:45PM	Salarius Pharmaceuticals to Present at Virtual H.C. Wainwright BioConnect, Participate in Virtual Biotech Showcase and BIO Partnering @ JPM During "J.P. Morgan Week 2022" GlobeNewswire -6.06%
Dec-29-21 08:03AM	Salarius Pharmaceuticals Achieves Dosing Milestone in Ongoing Phase 1/2 Sarcoma Trial GlobeNewswire -6.19%
Dec-20-21 08:35AM	Life Sciences Companies Investor Presentations Now Available for On-Demand Viewing CNW Group
Dec-15-21 08:31AM	Salarius Pharmaceuticals to Present at the Virtual Life Science Investor Forum GlobeNewswire
Dec-14-21 08:35AM	Virtual Conference for Life Sciences Companies Broadcast Live December 16th CNW Group
Nov-29-21 08:01AM	Salarius Pharmaceuticals to Participate in Annual Benchmark Company Discovery One-on-One Conference GlobeNewswire
Nov-04-21 04:05PM	Salarius Pharmaceuticals Reports Third Quarter 2021 Financial Results and Highlights Recent Company Progress GlobeNewswire
Oct-28-21 03:06PM	Will Salarius (SLRX) Report Negative Earnings Next Week? What You Should Know Zacks
Oct-26-21 08:01AM	Salarius Pharmaceuticals to Report Third Quarter 2021 Financial Results and Highlight Recent Company Progress GlobeNewswire
Oct-07-21 09:05AM	Salarius Pharmaceuticals and Nationwide Childrens Hospital Disclose Research Findings from Presentation at 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics GlobeNewswire
Oct-05-21 08:01AM	Salarius Pharmaceuticals to Present at the 2021 BioFuture Conference GlobeNewswire
Sep-30-21 04:35PM	Salarius Pharmaceuticals and Nationwide Childrens Hospital Announce Poster Presentation at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics GlobeNewswire
Sep-28-21 07:01AM	Salarius Pharmaceuticals Receives $2.7 Million in Payment from the Cancer Prevention and Research Institute of Texas GlobeNewswire
Sep-27-21 08:03AM	Salarius Pharmaceuticals to Present at the Virtual Benzinga Healthcare Small Cap Conference GlobeNewswire -5.22%
Sep-22-21 07:33AM	Salarius Pharmaceuticals and Fox Chase Cancer Center Launch Research Partnership GlobeNewswire
Sep-20-21 08:35AM	Life Sciences Companies Investor Presentations Now Available for On-Demand Viewing GlobeNewswire
07:33AM	Salarius Pharmaceuticals Added to FTSE Global Micro Cap Index GlobeNewswire
Sep-15-21 08:03AM	Salarius Pharmaceuticals to Present at the Virtual Life Science Investor Forum GlobeNewswire
Sep-10-21 08:35AM	Life Sciences Virtual Investor Conference: Company Executives Present Live September 16th GlobeNewswire
Sep-08-21 08:13AM	Salarius Pharmaceuticals to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference GlobeNewswire
Aug-12-21 02:00PM	Salarius Pharmaceuticals to Present at the Virtual Diamond Equity Research Emerging Growth Invitational GlobeNewswire
09:00AM	Diamond Equity Research Emerging Growth Invitational Summer 2021 Spotlight Virtual Conference GlobeNewswire
Aug-10-21 06:16AM	Here's Why We're Not Too Worried About Salarius Pharmaceuticals' (NASDAQ:SLRX) Cash Burn Situation Simply Wall St.
Aug-05-21 07:32AM	Salarius Pharmaceuticals Reports Second Quarter 2021 Financial Results and Highlights Recent Company Progress GlobeNewswire
Jul-29-21 07:33AM	Salarius Pharmaceuticals to Report Second Quarter 2021 Financial Results GlobeNewswire
Jul-14-21 08:05AM	Salarius Pharmaceuticals Announces Aundrietta Duncan, Ph.D., To Present During Virtual Epigenetic Therapeutic Targets Summit GlobeNewswire
Jul-13-21 07:33AM	Salarius Pharmaceuticals Adds Fox Chase Cancer Center to Ongoing Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas GlobeNewswire
Jul-09-21 07:33AM	Salarius Pharmaceuticals to Present at the Virtual Ladenburg Thalmann Healthcare Conference GlobeNewswire +7.92%
Jun-17-21 08:03AM	REMINDER: Salarius Pharmaceuticals to Host Virtual Key Opinion Leader and Investor Event GlobeNewswire
Jun-15-21 07:30AM	Salarius Pharmaceuticals Announces New Clinical Trial to Study Seclidemstat in Hematologic Cancers GlobeNewswire
Jun-10-21 01:30PM	Salarius Pharmaceuticals to Host Virtual Key Opinion Leader and Investor Event GlobeNewswire
Jun-07-21 07:35AM	Salarius Pharmaceuticals Presents New Research Data Demonstrating Seclidemstats Safety, Dosing, and Drug Activity at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting GlobeNewswire
May-19-21 05:01PM	Salarius Pharmaceuticals Discloses Key Findings from Three Abstracts to be Presented at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting GlobeNewswire -6.21%
May-12-21 04:05PM	Salarius Pharmaceuticals Reports First Quarter Financial Results with Business Highlights GlobeNewswire
02:45PM	Salarius Pharmaceuticals Inc to Host Earnings Call ACCESSWIRE
May-05-21 07:05AM	Salarius Pharmaceuticals to Report First Quarter 2021 Financial Results GlobeNewswire
Apr-29-21 07:30AM	Salarius Pharmaceuticals Announces Titles of Three Abstracts Accepted for Poster Presentations at American Society of Clinical Oncology 2021 Annual Meeting GlobeNewswire
Apr-19-21 07:30AM	Salarius Pharmaceuticals Announces Acceptance of Three Abstracts for Poster Presentations at the 2021 American Society of Clinical Oncology Annual Meeting GlobeNewswire
Mar-18-21 04:05PM	Salarius Pharmaceuticals Reports Business Highlights with Fourth Quarter and Full-Year 2020 Financial Results GlobeNewswire -5.06%
02:30PM	Salarius Pharmaceuticals Inc to Host Earnings Call ACCESSWIRE
Mar-11-21 04:15PM	Salarius Pharmaceuticals to Report Fourth Quarter and Full Year 2020 Financial Results GlobeNewswire +5.37%
Mar-08-21 04:05PM	Salarius Announces Closing of $23 Million Underwritten Public Offering of Common Stock Following Full Exercise of Over-Allotment Option GlobeNewswire +5.47%
Mar-04-21 08:30AM	Salarius Announces Pricing of $20 Million Underwritten Public Offering of Common Stock GlobeNewswire -16.15%
Mar-03-21 04:05PM	Salarius Announces Proposed Public Offering of Common Stock GlobeNewswire -13.90%
Feb-24-21 07:00AM	Salarius Pharmaceuticals Initiates Expansion Stage of Phase 1/2 Clinical Trial of Seclidemstat in Patients with Ewing Sarcoma and Ewing-Related Sarcomas GlobeNewswire +10.36%
Feb-22-21 07:30AM	Salarius Pharmaceuticals to Present at the Diamond Equity Research Emerging Growth Invitational Virtual Conference GlobeNewswire -9.62%
Feb-17-21 09:00AM	Diamond Equity Research Emerging Growth Invitational Winter 2021 Virtual Conference ACCESSWIRE
07:30AM	Salarius Completes Dose-Escalation Stage of Phase 1/2 Clinical Trial in Relapsed and Refractory Ewing Sarcoma Patients, Initiates Expansion Stage in Ewing and Ewing-Related Sarcoma Patients GlobeNewswire
Feb-16-21 07:30AM	Salarius Pharmaceuticals to Present at BIO CEO & Investor Digital Conference GlobeNewswire
Feb-10-21 06:21AM	Did Business Growth Power Salarius Pharmaceuticals' (NASDAQ:SLRX) Share Price Gain of 236%? Simply Wall St. +6.76%
Jan-21-21 08:05AM	Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement GlobeNewswire -6.67%
Jan-15-21 07:30AM	Salarius Pharmaceuticals Announces Dr. Daniela Santiesteban to Participate in Panel Discussion on Targeted Cancer Therapies During Virtual NobleCon17 Investor Conference GlobeNewswire
Jan-13-21 07:30AM	Salarius Pharmaceuticals Receives Second Installment of $1.7 Million in Payments from the Cancer Prevention and Research Institute of Texas GlobeNewswire
Dec-22-20 07:30AM	Salarius Pharmaceuticals to Participate in Biotech Showcase Digital and BIO @ JPM During "J.P. Morgan Week 2021" GlobeNewswire
Dec-11-20 11:32AM	Salarius Announces Exercise Of Warrants For $3.5 Million Of Gross Proceeds To Be Used For Ongoing Development Of Seclidemstat GlobeNewswire -31.34%
Dec-10-20 09:28AM	Salarius Pharmaceuticals Receives First Installment of $1.7 Million in Payments from the Cancer Prevention and Research Institute of Texas GlobeNewswire +24.07%
Nov-17-20 07:30AM	Salarius Pharmaceuticals to Participate in A.G.P.s Virtual Healthcare Symposium GlobeNewswire
Nov-11-20 04:05PM	Salarius Pharmaceuticals Reports Business Highlights and Third Quarter 2020 Financial Results GlobeNewswire
02:30PM	Salarius Pharmaceuticals Inc to Host Earnings Call ACCESSWIRE
Nov-04-20 07:30AM	Salarius Pharmaceuticals to Report Third Quarter 2020 Financial Results GlobeNewswire
Oct-13-20 07:30AM	Salarius Pharmaceuticals to Present at BIO Investor Forum Digital GlobeNewswire
Sep-21-20 08:35AM	Life Sciences Companies Investor Presentations Now Available for On-Demand Viewing GlobeNewswire
Sep-14-20 08:35AM	Virtual Conference for Life Sciences Companies Broadcast Live September 17th, 2020 GlobeNewswire +6.37%
Sep-10-20 07:30AM	Salarius Pharmaceuticals to Present at Upcoming Investor Conferences GlobeNewswire
Aug-27-20 10:00AM	Salarius Pharmaceuticals to Present During Virtual LD 500 Conference GlobeNewswire
Aug-12-20 04:05PM	Salarius Pharmaceuticals Reports Business Highlights and Second Quarter 2020 Financial Results GlobeNewswire
Aug-06-20 02:01PM	LD Micro: Announces Preliminary List of Presenters for the LD-500. ACCESSWIRE -5.56%
Aug-05-20 09:30AM	Salarius Pharmaceuticals to Report Second Quarter 2020 Financial Results GlobeNewswire +5.88%
07:30AM	Salarius Announces Issuance of New Patent for Seclidemstat by European Patent Office GlobeNewswire
Aug-03-20 04:05PM	Salarius Announces Closing of $6.2 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option GlobeNewswire
Jul-30-20 09:22AM	Salarius Announces Pricing of $5.3 Million Underwritten Public Offering GlobeNewswire -11.11%
Jul-29-20 04:15PM	Salarius Announces Proposed Public Offering of Common Stock GlobeNewswire
04:05PM	Salarius Pharmaceuticals to Expand Clinical Program to Target Additional Sarcomas in Ewing Sarcoma Phase 1/2 Clinical Trial GlobeNewswire
Jul-28-20 08:00AM	Salarius Pharmaceuticals Announces Move to New Corporate Offices at Texas Medical Center GlobeNewswire
Jul-23-20 08:00AM	Salarius Pharmaceuticals Names Nadeem Mirza, M.D., M.P.H., as Senior Vice President Clinical Development GlobeNewswire
Jun-02-20 09:00AM	Salarius Pharmaceuticals Invited to Present Seclidemstat Research at Meeting of the Pediatric Oncology Subcommittee of the Food and Drug Administrations Oncologic Drugs Advisory Committee GlobeNewswire +13.21%
May-27-20 08:00AM	Salarius Pharmaceuticals to Present Trial in Progress Poster at ASCO20 Virtual Scientific Program GlobeNewswire
May-22-20 09:24AM	Here's Why We're A Bit Worried About Salarius Pharmaceuticals's (NASDAQ:SLRX) Cash Burn Situation Simply Wall St.
May-14-20 04:05PM	Salarius Pharmaceuticals Reports First Quarter 2020 Financial Results GlobeNewswire
08:00AM	Salarius Pharmaceuticals Announces Acceptance of Abstract for 2020 ASCO Virtual Scientific Program GlobeNewswire
May-07-20 04:05PM	Salarius Pharmaceuticals to Report First Quarter 2020 Financial Results GlobeNewswire
Apr-29-20 07:30AM	Salarius Pharmaceuticals Announces Board of Director Nominations in Advance of 2020 Annual Meeting GlobeNewswire -8.77%
Apr-22-20 08:00AM	Salarius Pharmaceuticals to Deliver Virtual Presentation at the Emerging Growth Invitational GlobeNewswire
Apr-13-20 03:15PM	Houston pharmaceutical co. at risk of delisting from stock exchange American City Business Journals -5.72%
Mar-23-20 04:18PM	Salarius Pharmaceuticals Reports Fourth Quarter and Full-Year 2019 Financial Results GlobeNewswire -5.77%
Mar-04-20 08:00AM	Salarius Announces Allowance of New European Patent Covering Seclidemstat GlobeNewswire +9.18%
Mar-02-20 08:00AM	Salarius Pharmaceuticals to Attend the Oppenheimer Healthcare Conference GlobeNewswire +7.75%

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Rosenblum Mark J	Exec VP Finance, CFO	Mar 03	Buy	0.39	76,246	29,812	110,319	Mar 09 04:03 PM
Arthur David J.	Chief Executive Officer	Mar 03	Buy	0.39	139,488	54,540	249,674	Mar 09 04:01 PM
Arthur David J.	Chief Executive Officer	Aug 17	Buy	0.90	4,000	3,582	102,247	Aug 17 04:08 PM
HANISH ARNOLD C	Director	Aug 10	Buy	0.88	7,000	6,167	18,350	Aug 11 04:08 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience